Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients with Glomerulonephritis by Chin, Ho Jun et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Effect of RAAS Inhibition on the Incidence of Cancer and  
Cancer Mortality in Patients with Glomerulonephritis
Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with 
glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 
patients with renal biopsy and analyzed the relationship between the use of renin-
angiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer 
mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 
1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer 
incidence among the groups according to the use of angiotensin-converting enzyme 
inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% 
in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The 
cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and 
ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with 
ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox’s hazard 
proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does 
not increase cancer incidence and recipients of ARB show rather lower rates of all-cause 
mortality and cancer mortality.
Key Words: Glomerulonephritis; Neoplasms; Angiotensin II Type 1 Receptor Blockers  
Ho Jun Chin
1,2,3, Se Won Oh
1, 
Ho Suk Goo
2, Jieun Oh
4, Jung Woo Noh
4, 
Jong Tae Cho
5, Ki Young Na
1,3, 
Suhnggwon Kim
2,3, Dong-Wan Chae
1,2,3, 
and Members of The PREMIER Group
6
1Department of Internal Medicine, Seoul National 
University Bundang Hospital, Seongnam; 
2Kidney 
Research Institute, Medical Research Center, Seoul 
National University College of Medicine, Seoul; 
3Department of Internal Medicine, Seoul National 
University College of Medicine, Seoul; 
4Department 
of Internal Medicine, Hallym University College of 
Medicine, Chuncheon; 
5Department of Internal 
Medicine, Dankook University College of Medicine, 
Cheonan, Korea; 
6Members of the PREMIER Group
Received: 31 October 2010
Accepted: 8 December 2010
Address for Correspondence:
Dong-Wan Chae, MD
Department of Internal Medicine, Seoul National University 
Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 
463-787, Korea
Tel: +82.31-787-7004, Fax: +82.31-787-4052
E-mail: mednep@snubh.org
This study was supported by the Collaborative Research Grant 
of Korean Society of Nephrology.
DOI: 10.3346/jkms.2011.26.1.59  •  J Korean Med Sci 2011; 26: 59-66
ORIGINAL ARTICLE
Nephrology
INTRODUCTION
Glomerulonephritis (GN) is the third leading cause of end stage 
renal disease (ESRD) in the Korean population (1). Although 
the incidence of GN can be dependent on the indication for re-
nal biopsy and the medical environment (2), it ranges from 1 to 
16 new cases/year/10
5 adult population (3, 4). GN is related to 
increased other cause co-morbidities and mortality. The cumu-
lative incidence of ESRD among GN patients was 13% in 10 yr 
after biopsy in Denmark (5) and 17% during 17 yr after renal bi-
opsy in Japan (6). Patients with GN had higher incidence of all 
vascular complications compared to the general population (5). 
The mortality rate in GN patients was 32% at 10 yr after biopsy, 
which is a higher mortality rate relative to the general population 
for all pathologic diagnoses (5). GN was also related to a higher 
incidence of malignancy (7).The incidence of cancer was mark-
edly higher in patients with membranous nephropathy (MN) 
than in the general population (standardized incidence ratio of 
9.8 for men and 12.3 for women) (8) and also higher in other 
pathologic types (9-11). 
  Since the mid 1990s, the renoprotective effect of the blockades 
of renin-angiotensin-aldosterone system (RAAS) in diabetic and 
non-diabetic nephropathies was reported, although argument 
continues about the additional effect of RAAS blockades beyond 
lowering blood pressure (12). As a result, RAAS blocking agents 
were widely applied to clinical medicine and GN treatment (13). 
An important meta-analysis recently published suggested that 
angiotensin II type 1 receptor blockers (ARB) are associated with 
an increased risk of new cancer diagnosis (14). Considering the 
wide use of ARB and the higher incidence of malignancy in pa-
tients with GN, we should confirm the relationship between ARB 
prescription and cancer incidence. In this study, we registered 
patients with renal biopsy, determined the prevalence and inci-
dence of malignancy, mortality rate, and cancer mortality rate, 
and analyzed the relationship between the use of RAAS block-
ades and cancer incidence or mortality.  Chin HJ, et al.  •  Cancer and RAAS Inhibition in GN
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MATERIALS AND METHODS
Study subjects
The subjects who had diagnosed and been followed as glomer-
ulonephritis by the renal biopsy were enrolled in the Progressive 
REnal disease and Medical Informatics and gEnomics Research 
(PREMIER) program sponsored by the Korean Society of Ne-
phrology, retrospectively (13, 15, 16). Thirty-four hospitals and 
clinics in Korea participated in the study. We included 3,288 
adult patients, who had been enrolled during August 2003 to 
December 2005, in the analysis. 
Data
The participating researchers had selected patients with renal 
biopsy and one qualified nurse, who had visited every partici-
pated institution, inputted the data into the formatted database. 
We collected final diagnoses of renal pathology in the format of 
minimal change lesion (MCN), MN, focal segmental GN (FSGS), 
membranoproliferative GN (MPGN), IgA nephropathy (IgA), 
Henoch-Schölein nephritis (HSP), lupus nephritis (Lupus), 
Crescentic GN (Cresentic), diabetic nephropathy (DMN), and 
diagnosis not otherwise classified (Others). The pathologic di-
agnosis was decided by the pathologists in each center. We de-
fined the user-group of medication, such as angiotensin-con-
verting enzyme inhibitors (ACEI), ARB, and any kind of steroid 
and HMG-CoA reductase inhibitor if it was prescribed for more 
than 3 months, and started within 6 months after renal biopsy. 
Hypertension was defined as a reported history of hypertension, 
a systolic blood pressure (SBP) of 140 mmHg or more, or a dia-
stolic blood pressure (DBP) of 90 mmHg or more. Diabetes mel-
litus was defined as a random glucose level 200 mg/dL or more 
or a reported history of diabetes. We grouped patients as no med-
ication of ACEI or ARB (None), ACEI-only, ARB-only, and ACEI 
and ARB (ACEI-ARB). The estimated glomerular filtration rate 
(eGFR) was calculated by the modified modification of diet in 
renal disease equation based on the Jaffe method to measure 
serum creatinine (17).
The outcomes
The endpoints were the development of new cancer and death 
by any cancer after renal biopsy. The mortality data were ob-
tained from Statistics Korea. The institution provided the cause 
of death for an individual patient until December 2006. The pri-
mary cause of death was reported by a doctor to the government 
in ICD-10 disease code. The incidence of cancer was obtained 
from the Korean National Cancer Center that has collected the 
data of cancer in Korea since 1980 (18). We could join the data 
based on the unique personal identifier which all Koreans have. 
Statistical analysis
The SPSS (SPSS version 15.0, Chicago, IL, USA) package was used 
for statistical analysis. Differences in proportions were compared 
by chi-square test. Group differences for continuous variables 
were assessed by the Student t-test or one-way ANOVA test ac-
cording to the number of groups. We compared the cumulative 
incidence of outcomes after renal biopsy by Log-rank test. The 
cancer occurrence was compared with that of the general pop-
ulation, taking into account of gender, age, and period of renal 
biopsy, and the 95% confidence interval (CI) for the observed-
to-expected rate was calculated. Expected cases were calculat-
ed for each 5-yr stratum of the cohort and by gender. National 
estimates of overall and organ-specific cancer incidence by gen-
der and 5-yr age group were provided by Statistics Korea. To de-
termine whether the user of ACEI or ARB was independently 
related to the incidence of cancer or mortality by cancer, we used 
Cox’s hazard proportional analysis. Two-sided P values were 
reported with 0.05 taken as the level of statistical significance. 
All data are shown as mean ± standard deviation for continuous 
variables or frequency per observation for nominal variables.
Ethnic statement
This study was approved by the institutional review board (IRB) 
in Seoul National University Bundang Hospital (IRB approval 
number: B-0409/012-003) and other participating hospitals. 
This study was a retrospective study for which IRB in Seoul Na-
tional University Bundang Hospital waived patients’ consent to 
review medical records.
RESULTS 
Characteristics of patients at renal biopsy 
The study sample of 3,288 patients (1,866 males and 1,422 fe-
males) had accrued 9,078 person-years (4,109 for males and 
4,969 for females) to detect cancer incidence. The mean age at 
biopsy was 41.4 yr in all patients and was the lowest in the None 
group (Table 1). The male proportion did not differ among the 
groups. ARB and/or ACEI were used in 40.4% of the patients. 
Mean eGFR was 72.0 mL/min/1.73 m
2 and was the lowest in 
the ACEI-ARB group. There were 87 patients with cancer diag-
nosed before renal biopsy and the proportion of those patients 
were not different among the groups. 
Kidney pathology
The most frequent diagnosis was IgA nephropathy (44.9%) (Table 
2). The frequencies of MCN and Others were higher in the None 
group, those of MN and MPGN were higher in the ACEI-ARB 
group, and that of IgA nephropathy was the highest in the ARB-
only group. Male was predominant in every diagnosis except 
Lupus. The mean age at biopsy was the lowest in Lupus (34.5 ± 
11.0 yr) and the highest in DMN (54.5 ± 12.9 yr). Hypertension 
was the most common in DMN (87.8%) and the least in MCN 
(32.0%). Chin HJ, et al.  •  Cancer and RAAS Inhibition in GN
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The incidence of cancer and risk factors to cancer 
development 
After renal biopsy, the cancer was developed in 33 patients (13 
females and 20 males) by December 2005 and the incidence 
rate, adjusted for age and gender, was 1.0% (95% of CI for inci-
dence: 0.7%-1.3%). The cancer was diagnosed in 23 patients with-
in 1 yr, in 6 during 2-3 yr, in 2 during 4-5 yr, and in 2 during more 
than 5 yr after biopsy. The most frequent cancer was stomach 
cancer (9 patients), followed by thyroid cancer (6), lung cancer 
(3), multiple myeloma (3), colon cancer (2), hepatic cancer (2), 
Non-Hodgkin’s lymphoma (2), prostatic cancer (2), cervical can-
cer (1), esophageal cancer (1), kidney cancer (1), and pancreat-
ic cancer (1). Overall, the incidence of cancer was significantly 
higher in the patients than in the general population, especially 
in those aged 65 yr or more (Table 3). Male and female patients 
showed a 2.481- and 3.270-fold higher rate of cancer incidence, 
respectively, compared to the general population. The develop-
ment of cancer was frequent in MN (2.8%, 8/287), DMN (2.7%, 
2/74), MPGN (2.4%, 3/127), and Crescentic (2.3%, 1/43). There 
was 1 case (0.6%) of cancer in 164 Lupus patients, 0.4% (1/235) 
Table 1. Characteristics of patients at renal biopsy
Parameters All (n = 3,288) None (n = 1,960) ARB-only (n = 748) ACEI-only (n = 247) ACEI-ARB (n = 333) P value*
Gender (male) 1,866 (56.8) 1,123 (57.3) 149 (60.3) 395 (52.8) 199 (59.8) 0.058
Age (yr)    41.4 ± 16.0   40.2 ± 16.4
a   43.3 ± 15.1
b   43.2 ± 15.7
b   42.9 ± 15.1
b < 0.001
Hypertension 1,428 (43.4) 727 (37.1) 378 (50.5) 122 (49.4) 201 (60.4) < 0.001
Diabetes 200 (6.1) 117 (6.0) 48 (6.4) 15 (6.1) 20 (6.0) 0.979
History of CVA   27 (0.8)   16 (0.8)   6 (0.8)   1 (0.4)   4 (1.2) 0.772
History of CHD   23 (0.7)   15 (0.8)   3 (0.4)   4 (1.6)   1 (0.3) 0.183
History of cancer   87 (2.6)   56 (2.9) 23 (3.1)   3 (1.2)   5 (1.5) 0.322
Duration of cancer
†   31.8 ± 44.8  28.1 ± 42.4  34.9 ± 43.9  35.1 ± 53.1  57.3 ± 72.8 0.555
SBP (mmHg) 128.5 ± 19.1 127.6 ± 18.9
a 128.5 ± 18.8
a 127.9 ± 16.8
a 133.6 ± 21.8
b < 0.001
DBP (mmHg)   80.2 ± 12.4   79.6 ± 12.4
a   80.3 ± 11.8
a   80.6 ± 12.2
a   82.6 ± 14.0
b 0.001
eGFR (mL/min/1.73 m
2)
   > 90
   75-89
   60-74
   45-59
   40-44
   < 30
   Data missing
  72.0 ± 38.3
  929 (28.3)
  546 (16.6)
  532 (16.2)
  417 (12.7)
313 (9.5)
  427 (13.0)
124 (3.8)
  74.0 ± 41.7
a
  620 (31.6)
  325 (16.6)
  271 (13.8)
  210 (10.7)
179 (9.1)
  271 (13.8)
  84 (4.3)
   69.2 ± 32.5
a,b
176 (23.5)
120 (16.0)
153 (20.5)
123 (16.4)
67 (9.0)
  87 (11.6)
22 (2.9)
   72.1 ± 33.8
a,b
  65 (26.3)
  38 (15.4)
  53 (21.5)
  35 (14.2)
  29 (11.7)
20 (8.7)
  7 (2.8)
  66.8 ± 31.8
b
  68 (20.4)
  63 (18.9)
  55 (16.5)
  49 (14.7)
  38 (11.4)
  49 (14.7)
11 (3.3)
0.002
< 0.001
Medication
‡
   Statin
   Steroid
  566 (17.2)
  581 (17.7)
  96 (4.9)
  229 (11.7)
244 (32.6)
197 (26.3)
  53 (21.5)
  57 (23.1)
173 (52.0)
  98 (29.4)
< 0.001
< 0.001
Biopsy period
   1982-2001
   2002-2003
   2004
   2005
  683 (20.8)
  827 (25.2)
  884 (26.9)
  894 (27.2)
  492 (25.1)
  578 (29.5)
  499 (25.5)
  391 (19.9)
  98 (13.1)
107 (14.3)
212 (28.3)
331 (44.3)
  50 (20.2)
  86 (34.8)
  71 (28.7)
  40 (16.2)
  43 (12.9)
  56 (16.8)
102 (30.6)
132 (39.6)
< 0.001
*Statistics of difference among medication groups, alphabet on right upper part of data: the same character indicates no difference between groups by Duncan post-hoc 
analysis; 
†Time interval (months) from date of diagnosis of cancer to date of renal biopsy in patients who had diagnosed cancer before renal biopsy, 
‡drugs prescribed for more 
than 3 months, started within 6 months after renal biopsy. ARB, angiotensin II type I receptor blocker. ACEI, angiotensin-converting enzyme inhibitors; CVA, cardiovascular 
accident; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.
Table 2. The pathologic diagnosis of patients
Pathologic diagnosis Total None   ARB-only ACEI-only ACEI-ARB P value*
MCN 172 (5.2) 130 (6.6) 28 (3.7) 6 (2.4) 8 (2.4) < 0.001
MN 287 (8.7) 141 (7.2) 76 (10.2) 29 (11.7) 41 (12.3) 0.001
FSGS 235 (7.1) 130 (6.6) 51 (6.8) 23 (9.3) 31 (9.3) 0.172
MPGN 127 (3.9) 70 (3.6) 26 (3.5) 7 (2.8) 24 (7.2) 0.009
IgA 1,477 (44.9) 818 (41.7) 382 (51.1) 117 (47.4) 160 (48.0) < 0.001
HSP 66 (2.0) 33 (1.7) 22 (2.9) 5 (2.0) 6 (1.8) 0.218
Lupus 164 (5.0) 101 (5.2) 34 (4.5) 16 (6.5) 13 (3.9) 0.493
Crescentic 43 (1.3) 27 (1.4) 10 (1.3) 3 (1.2) 3 (0.9) 0.914
DMN 74 (2.3) 41 (2.1) 18 (2.4) 5 (2.0) 10 (3.0) 0.748
Others 643 (19.6) 469 (23.9) 101 (13.5) 36 (14.6) 37 (11.0) < 0.001
*Statistics of difference among medication groups. ARB, angiotensin II type I receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; MCN, minimal change lesion; MN, 
membranous nephropathy; FSGS, focal segmental glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; IgA, IgA nephropathy; HSP, Henoch-Schölein nephritis; 
Lupus, lupus nephritis; Crescentic, Crescentic glomerulonephritis; DMN, diabetic nephropathy; Others, Not otherwise classified.Chin HJ, et al.  •  Cancer and RAAS Inhibition in GN
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in FSGS, 0.7% (10/1477) in IgA, none in HSP, and 0.6% (1/172) 
in MCN. In females, the incidence rate of cancer among patients 
with IgA (7/642) was 4.906-fold (95% CI: 1.980-10.033) higher 
and, in males, the incidence rates of cancer among patients with 
MN (6/177) and MPGN (3/86) were 4.467- (95% CI: 1.647-9.528) 
and 6.288-fold (95% CI: 1.316-17.773) higher compared to the 
general population, respectively. Other pathologic diagnoses 
did not exhibit any differences between the patients and the 
general population.
  Cancers were found in excess in the pancreas, lung, and thy-
roid in female patients, and in the stomach and kidney in male 
patients than in general population. Non-Hodgkin’s lymphoma 
and multiple myeloma were diagnosed more frequently in pa-
tients compared to the general population (Table 4). There was 
no difference of estimated cancer incidence after biopsy among 
the groups according to the use of ACEI or ARB (Fig. 1A). Cancer 
was developed in 23 (1.2%) patients of the None, 5 (0.7%) of the 
ARB-only, 1 (0.4%) of the ACEI-only, and 4 (1.2%) of the ACEI-
ARB (P = 0.487) groups. With Cox’s hazard proportional analysis, 
medication with ACEI or ARB was not a related factor to cancer 
incidence (Table 5). 
The incidence of all-cause mortality and cancer mortality 
There were 153 deaths (4.7%) caused by malignancy (45), renal 
disease (38), cardiovascular disease (24), hepatic failure (8), in-
fection (7), SLE (6), and miscellaneous causes (26) until Decem-
ber 2006. Among 87 patients with cancer diagnosed before renal 
biopsy, 28 patients were dead due to malignancy and the other 
Table 3. Observed, expected, and observed/expected rate of 33 cancers after renal biopsy
Age
Female Male
% Total   O* E
† O/E (95% CI) % Total O E O/E (95% CI)
< 55 0.53% 1,122   6 2.023  2.966 (1.109-6.435) 0.35% 1,434   5 1.682  2.973 (0.938-6.906)
55-64 1.18%    169   2 0.870  2.299 (0.272-8.180) 1.72%    233   4 2.296  1.742 (0.477-4.404)
> 65 3.82%    131   5 1.083    4.616 (1.512-10.497) 5.53%    199 11 4.084  2.694 (1.360-4.717)
Total 0.91% 1,422 13 3.976  3.270 (1.753-5.580) 1.07% 1,866 20 8.062  2.481 (1.528-3.819)
*Number of incident cancers observed in patients with glomerulonephritis; 
†expected number of cancers in this patients, estimated using 2000-2005 cancer incidence rates in 
the Korean population.
Table 4. Excess cancers in each gender after renal biopsy 
Female   O*  E
† O/E (95% CI)
Stomach cancer (C16) 2 0.56  3.593 (0.511-13.028)
Pancreas cancer (C25) 1 0.09  11.747 (1.670-65.149)
Lung cancer (C33-C34) 2 0.26  7.834 (1.114-28.490)
Cervical cancer (C53) 1 0.34  2.917 (0.415-16.180)
Thyroid cancer (C73) 4 0.51  7.780 (2.213-19.914)
NHL (C82-C85, C96) 1 0.08  13.181 (1.874-73.099)
Multiple myeloma (C90) 2 0.02  104.023 (14.792-377.198)
Male   O*  E
† O/E
Esophageal cancer (C15) 1 0.22  4.489 (0.838-25.129)
Stomach cancer (C16) 7 1.84  3.805 (1.521-7.809)
Colon cancer (C18-C20) 2 0.47  4.221 (0.394-15.360)
Hepatic cancer (C22) 2 1.22  1.642 (0.153-5.973)
Lung cancer (C33-C34) 1 1.40  0.713 (0.133-3.991)
Prostatic cancer (C61) 2 0.31  6.407 (0.598-23.312)
Kidney cancer (C64-65) 1 0.08  12.611 (2.353-70.594)
Thyroid cancer (C73) 2 0.10  19.918 (0.009-72.477)
NHL (C82-C85, C96) 1 0.16  6.433 (1.200-36.012)
Multiple myeloma (C90) 1 0.04  25.037 (4.672-140.157)
*Number of incident cancers observed in patients with glomerulonephritis; 
†ex  pected 
number of cancers in this patients, estimated using 2000-2005 cancer inci  dence 
rates in the Korean population, cancer classified by ICD-10 code. NHL, Non-Hodgkin’s 
lymphoma.
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Fig. 1. The incidence of cancer and cancer mortality after kidney biopsy. (A) Incidence of cancer, (B) Incidence of cancer mortality. There was no difference between None and 
other three groups in cancer incidence, also (P = 0.568). The cancer mortality in None group was higher than other 3 groups, too (P < 0.001).Chin HJ, et al.  •  Cancer and RAAS Inhibition in GN
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17 deaths were in patients with cancer diagnosed after renal bi-
opsy. Most deaths (76.5%) occurred within 24 months after bi-
opsy and the mean duration from biopsy to death was 17.4 ± 
23.7 (0.1-183.3) months in the deceased patients (Fig. 1B). The 
independent risk factors to death were age, eGFR, history of can-
cer diagnosed before biopsy, renal pathology, and usage of ACEI 
or ARB with Cox’s hazard proportional analysis adjusted with 
adjustment for age, gender, diabetes, hypertension, history of 
CVA, CHD, and cancer diagnosed before kidney biopsy, eGFR, 
usage of steroid and statin, year at biopsy, and renal pathology.
  Users of ARB-only, ACEI-only, and ACEI and ARB had mor-
tality risk of 0.263 (0.137-0.504), 0.442 (0.191-1.023), and 0.453 
(0.198-1.035)-folds compared to the None-user group by Cox’s 
hazard proportional analysis, respectively. The number of deaths 
due to cancer was 41 (2.1%) in None and 4 (0.2%) in the other 
groups (P < 0.001), that is, 3 (0.4%) in ARB-only, 0 (0.0%) in ACEI-
only, and 1 (0.3%) in ACEI-ARB (P < 0.001) groups. The indepen-
dent risk factors to cancer mortality were age, history of cancer, 
and ARB usage. The risk of cancer mortality in patients with ARB 
was 0.124-fold (0.034-0.445) compared to non-users of ARB 
(Table 5). 
DISCUSSION
We confirmed that the GN patients showed a higher incidence 
of cancer, especially in patients with MN, MPGN, and IgA, or 
patients aged more than 65 yr, compared to the general popula-
tion. The cancer types more frequently diagnosed in GN pati-
ents than in the general population were Non-Hodgkin’s lym-
phoma, multiple myeloma, stomach cancer, kidney cancer, pan-
creas cancer, lung cancer, and thyroid cancer, which were usu-
ally diagnosed within 1 yr after renal biopsy. The use of ARB was 
an important prognostic factor to decrease cancer mortality with-
out increasing cancer incidence after renal biopsy. The leading 
cause of mortality in GN patients was malignancy followed by 
renal disease and cardiovascular diseases.
  Cancer occurs in 11% to 13% of patients with the nephritic 
syndrome (7, 19) and reaches as high as 24.6% in patients over 
65 yr presenting with MN (8). The incidence of cancer in GN 
patients compared to the general population is increased de-
pendent on the age and duration of observation after renal bi-
opsy. Cancer incidence is increased 2.4- to 3.5-fold at < 1 and 1 
to 4 yr, respectively, but not for five years or more after renal bi-
opsy (9) and is increased 13.2-fold in older female patients with 
MN, but not in females aged less than 65 yr (8). Although the 
well-known type of GN related to malignancy is MN (8), cancer 
excess is also observed in other pathologic types, such as IgA 
nephropathy, MPGN, and minimal change lesion (8, 20). He-
matologic malignancies such as lymphoma and myeloma are 
most frequently reported among various types of cancer related 
to GN (9). 
  Recently, a meta-analysis of a randomized controlled study 
showed that patients receiving ARB had a significant increased 
risk of new cancer compared with patients in a control group 
(14). However, they pooled the results of studies that were not 
designed to explore cancer outcomes and did not adjust for any 
risk factors to cancer development (14). Therefore, further stud-
ies are required to confirm these findings. 
  Few clinical reports have targeted the effect of ARB on cancer 
incidence. A cohort study, using data of the randomized Depart-
ment of Veterans Affairs Topical Tretinoin Chemoprevention 
trial, showed that users of ACEIs or ARBs had a lower incidence 
of keratinocyte cancers than non-users among 1,051 participants 
with a high risk of skin cancers (21). Although only 27 partici-
pants used ARB compared to 505 using ACEI, users of either of 
the two had two-thirds the rate of basal cell carcinoma compared 
to non-users during up to 6-yr follow-up period (21). Among 
Chinese women in Singapore, genetic polymorphisms in the 
5’-regions in angiotensin II type 1 receptor (AT1R) gene (A-168G, 
C-535T, and T-825A) were studied in the aspect of breast cancer 
risk (22). Relative to the homozygotes (AA, CC, and TT), individ-
ual genotypes with one or two copies of putative low-risk geno-
types were each associated with a -30% reduction in breast can-
cer risk (22). In an in vitro study, angiotensin II stimulated the 
proliferation of a human breast adenocarcinoma cell line via AT1R 
and was involved in the pathogenesis of premalignant lesions 
(23). Those findings suggested AT1R activity might be linked to 
breast cancer risk. 
  In the present study, there was no increase of cancer incidence 
related to the use of ACEI or ARB among GN patients but the use 
of ARB was related to decrease of all-cause mortality and can-
cer mortality. In patients with GN, the incidence of all vascular 
Table 5. Cox’s hazard proportional analysis for outcomes
For incidence of cancer*
B P value OR 95% CI for OR
User of ACEI or ARB*
   ARB-only
   ACEI-only
   ACEI and ARB
-0.366 
-1.259 
0.192
0.530 
0.487 
0.221 
0.755 
0.693 
0.284
1.212 
0.247
0.038 
0.363 
1.947 
2.137
4.044 
User of ACEI* -0.235  0.643 0.791  0.293  2.136 
User of ARB* -0.040 0.927 0.961  0.409 2.257 
For cancer mortality
†
B P value OR 95% CI for OR
User of ACEI* -1.754  0.092  0.173  0.023  1.329 
User of ARB* -2.090  0.001  0.124 0.034  0.445 
*Analysis for cancer incidence was done with adjustment for age, gender, cancer 
diagnosed before kidney biopsy, usage of steroid, statin, ACEI, or ARB, year at biopsy, 
and renal pathology, user of ACEI or ARB: compared to non-user of ACEI and ARB, 
User of ARB: patients stratified with user or non-user of ARB and compared with non-
user, user of ACEI: patients stratified with user or non-user of ACEI and compared with 
non-user; 
†Analysis for cancer mortality was done with adjustment for age, gender, 
diabetes, hypertension, history of CVA, CHD, and cancer diagnosed before kidney 
biopsy, eGFR, usage of steroid and statin, year at biopsy, and renal pathology. ACEI, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin II type I receptor blocker.Chin HJ, et al.  •  Cancer and RAAS Inhibition in GN
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complications, such as acute myocardial infarction or cerebral 
thrombosis, was higher than in the general population (5). In 
this aspect, it was surprising that the most common cause of 
death was cancer in this study. Age was the most important fac-
tor in the cancer incidence of MN, which is a well known type 
of GN associated with malignancy (8). The mean age of patients 
in this study was higher than that of other studies (5, 6), which 
might explain the higher incidence of cancer mortality. The block-
ade of RAAS was not proved to improve overall mortality in pa-
tients with diabetes or at high risk for cardiovascular disease 
(24), although few large studies have examined patients with 
GN. In this study, ARB usage decreased the mortality, especially 
in cancer mortality. The relationship between cancer mortality 
and ARB usage was more evident in patients aged 50 yr or more 
(users:non-users = 4/357:34/623, P < 0.001) than in younger 
patients. Previously, candesartan (25) and telmisartan (26) were 
proposed to have the usefulness of the cytostatic activity in recur-
rent prostatic cancer. Recipients of either ACEI or ARB showed 
3.1-month longer median survival than non-recipients among 
patients with advanced non-small cell lung cancer (27). We could 
not identify the relationship between ARB usage and mortality 
due to lung cancer because only 8 such cases presented in our 
sample. 
  Several anti-cancer mechanisms have been suggested for 
ARB. Inhibition of angiotensin II by ARB or ACEI down-regu-
lates vascular endothelial growth factor (VEGF), which is impor-
tant in angiogenesis, and inhibites tumor growth (28). Inhibition 
of AT1R activity decreased leukocyte adhesion, extravasation, 
and inflammation, which are known risk factors for shorter sur-
vival in patients with advanced cancer (29). Stimulation of AT1R 
activates the mitogen-activated, protein kinase/signal transduc-
ers and activators of transcription pathways that play a role in 
the response to several growth factors regulating cell prolifera-
tion (30). 
  The present study suffered several limitations. The complete 
information about the histologic findings of light microscopy, 
immunofluorescence, and electron microscopy were not avail-
able in all patients. We gathered the defined pathologic diagno-
sis from many centers for a long period of diagnosis. The patho-
logic criteria also varied according to the pathologists and the 
time. Secondly, the initial laboratory findings were not complete, 
except the data showed in this presentation, and we could not 
evaluate the effect of other possible confounding variables that 
may have affected the incidence and mortality of cancer. Thirdly, 
the exact dose, brand name, and duration of treatment of ACEI 
or ARB were not specified. We defined users of medication as 
being the recipients of ACEI or ARB for more than 3 months, 
started within 6 months after renal biopsy. We could not evalu-
ate the dose responsiveness for outcomes to medication. Fourth-
ly, the primary cause of death was defined by doctors, but this 
definition may not have been applied consistently. The data were 
extracted from the national database and their exactness was 
not confirmed by the researchers. Fifthly, we could not evaluate 
the carcinogenic effect of cytotoxic agents, such as cyclophos-
phamide and azathioprin, which were used in the treatment of 
glomerulonephritis. 
  In conclusion, patients with GN show a higher incidence of 
cancer and cancer mortality compared with the general popula-
tion. Prescription of ACEI or ARB in patients with GN does not 
increase cancer incidence and recipients of ARB show rather to 
be lower rates of all-cause mortality and cancer mortality.
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Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients 
with Glomerulonephritis
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Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis, is suggested to 
increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of renin-
angiotensin-aldosterone system blockade and the incidence of cancer or cancer mortality. After renal biopsy, the cancer incidence 
was 1.0% (95% CI: 0.7-1.3%). There was no difference in the cancer incidence among the groups according to the use of 
angiotensin-converting enzyme inhibitors (ACEI) or ARB. The risk of cancer mortality in patients with ARB was only 0.124 (95% 
CI: 0.034-0.445) compared to that of non-users of ARB. In this study, prescription of ACEI or ARB in patients with GN does not 
increase cancer incidence and recipients of ARB show rather to be lower rates of all-cause mortality and cancer mortality.